Default company panoramic image
3caef194 bb9c 4c99 a3cf f4101a0c3cc5

Arataki Therapeutics Limited

A unique opportunity to participate in the improvement of compounds from AstraZenenca to treat Head & Neck and Non-Small Cell Lung Cancers.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Auckland, New Zealand
  • Currency NZD
  • Founded March 2012

Company Summary

Arataki has entered into an agreement with AstraZeneca PLC which provides exclusive access to proprietary cancer drugs to improve their efficacy utilising world-leading technology and expertise from the Auckland Cancer Society Research Centre. When such improvement is demonstrated, AstraZeneca has an Option to licence the improved drugs back from Company or it must licence its original drug candidates to Arataki.


  • Default avatar
    Jim Mervis
    Managing Director

    Mr Mervis has 20 years of experience in life science company start-ups, having been co-founder of Barrier Therapeutics (J&J dermatology spin-out) and Cardiokine (therapy for hyponatremia) as well as Chairman of Intercept Pharmaceuticals (therapies for liver disease) and Chairman of CoDa Therapeutics (therapies for wound healing). He is also currently Chairman of Auckland Uniservices Life Science Investment Committee.

  • Default avatar
    Professor Bill Wilson
    Founding Scientist & Leader of Biology:

    Prof Wilson has been responsible for discovery of two hypoxia-activated prodrugs (PR-104, jointly with Prof Bill Denny, and SN30000, jointly with A/Prof Hay) and is actively involved in the ongoing development of both agents – particularly through development of predictive biomarkers. He is a founder of Proacta Inc. He has authored over 220 peer-reviewed papers in drug development, tumour biology, tumour hypoxia and cancer pharmacology.

  • Default avatar
    Associate Professor Michael Hay
    Founding Scientist & Leader of Chemistry

    Assoc. Prof Hay's main research focus is anti-cancer drug development selectively targeting the tumour microenvironment through bioreductive mechanisms and/or selective target inhibition. He has developed the hypoxia-activated prodrug SN30000 in conjunction with Prof Bill Wilson, as well as the discovery of agents that selectively target hypoxia-inducible factor 1 (HIF-1) in collaboration with Prof Amato Giaccia, Stanford University.


  • Default avatar
    Minter Ellison

Previous Investors

  • Default avatar
    Auckland UniServices Ltd.
    Default avatar
    The University of Auckland